# Seguridad Oncológica de SLNB Sola Tras NAC en ypN0 (McGill/Jewish General)

**Autores:** Wong SM, Basik M, Florianova L, Margolese R, Dumitra S, Muanza T, Carbonneau A, Ferrario C, Boileau JF (McGill University)
**Revista:** Annals of Surgical Oncology (2020)
**PMID:** 33095362 | **PMCID:** —
**DOI:** [10.1245/s10434-020-09211-0](https://doi.org/10.1245/s10434-020-09211-0)
**Fuente:** PubMed (abstract only — full text vía DOI/institución)

## Relevancia
Cohorte que respalda la **omisión segura de ALND** cuando se demuestra ypN0 mediante SLNB sola tras NAC. Recurrencia axilar a 5 años: **0%** en el grupo cN1-2/ypN0 (n=58). Importante: 70.7% del grupo cN1-2/ypN0 recibió radioterapia regional, frente a 5% del grupo cN0/ypN0.

## Abstract

**Background:** The oncologic safety of sentinel lymph node biopsy (SLNB) alone for clinically node-positive (cN1-2) patients who convert to pathologic node-negativity (ypN0) after neoadjuvant chemotherapy (NAC) is not well established.

**Methods:** Retrospective study of 244 consecutive patients with cT1-3cN0-2 breast cancer who underwent NAC followed by SLNB at the authors' institution (2013-2018). Patients categorized as cN0 vs cN1-2 before NAC. Kaplan-Meier method compared recurrence rates after SLNB alone for ypN0 patients.

**Results:** Of 244 patients, 112 (45.9%) were cN0 at presentation, 132 (54.5%) had biopsy-proven cN1-2 disease and converted to cN0 after treatment. 102 (91.1%) cN0 patients were ypN0 on SLNB vs 60 (45.5%) cN1-2 patients (p<0.001). **Regional nodal irradiation:** 5% of cN0/ypN0 vs **70.7% of cN1-2/ypN0** (p<0.001). 211 patients treated with SLNB alone, median follow-up 36 months.

**For 101 cN0/ypN0 patients with SLNB alone:** 5-year local recurrence 5.7% (95% CI 2.4-13.8), regional 1% (95% CI 0.1-7.0).

**For 58 cN1-2/ypN0 patients with SLNB alone:** 5-year local recurrence 4.1% (95% CI 1.0-15.5), **regional 0%**, **no axillary recurrences noted**.

**Conclusion:** For ypN0 patients, SLNB alone after NAC is associated with low and acceptable short-term axillary recurrence rates.

## Acceso
Artículo no disponible en PMC. Acceder vía [DOI](https://doi.org/10.1245/s10434-020-09211-0) o suscripción institucional.

---
*Datos de PubMed. Citar: doi 10.1245/s10434-020-09211-0*
